Saarland University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Saarbrucken Germany (1948)

Organization Overview

First Clinical Trial
2000
NCT00146276
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Children`s Medical Hospital, University of Homburg/Saar, Homburg/Saar, Germany | Department of Clinical Chemistry, University of Saarland | Department of Neurology University Homborg Hospital of the Saarland, Germany | Dept. of Psychiatry and Psychotherapy, The Saarland University Hospital | Dept of Urology, Saarland University | Institute of Forensic Psychology and Psychiatry, University of Saarland | Medical Faculty of the University of the Saarland and Hospitals of the City of Cologne | Saarladnd University, Department of Neurology | Saarland University | Saarland University Hospital | Saarland University Medical Center | Saarland University Medical Centre | Saarland University, Saarland University Hospital | Universitaetsklinikum des Saarlandes | Universität des Saarlandes | Universität des Saarlandes, EEAST | Universitatskliniken des Saarlandes | Universitatskliniken des Saarlandes, Homburg, Germany | University des Saarlandes | University Hospital Homburg/Saar | University Hospital of Saarland, Dpt. of Internal Medicine IV, Div. of Nephrology and Hypertension | University hospital of the Saarland | University Hospital of the Saarland | University Hospital, Saarland | University of Saarland | University of the Saarland

Active Ingredients

Drugs in Phase 4 Trials (9)

amantadine (symmetrel) (1 trial)

ferric carboxymaltose (Injectafer) (1 trial)

ferric derisomaltose (Monoferric) (1 trial)

inactivated influenza vaccine (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

ivabradine (corlanor) (1 trial)

mannitol (Osmitrol) (1 trial)

moxifloxacin (avelox) (1 trial)

ribavirin (virazole) (1 trial)

Drugs in Phase 3 Trials (21)

bupropion (wellbutrin) (1 trial)

carboplatin (paraplatin) (1 trial)

cyclophosphamide (cytoxan) (7 trials)

dactinomycin (cosmegen) (1 trial)

doxorubicin (Doxil) (7 trials)

epoetin (Epogen) (2 trials)

etoposide (vepesid) (2 trials)

fatty acid (1 trial)

fluvastatin (lescol) (1 trial)

gemcitabine (gemzar) (2 trials)

hydrochlorothiazide (esidrix) (2 trials)

methylphenidate (ritalin) (1 trial)

olmesartan (benicar) (1 trial)

paclitaxel (taxol) (1 trial)

prednisone (meticorten) (7 trials)

rituximab (rituxan) (6 trials)

sargramostim (leukine) (3 trials)

sirolimus (rapamune) (1 trial)

tranexamic acid (cyklokapron) (1 trial)

tumor-pulsed dendritic cells (1 trial)

vincristine (oncovin) (8 trials)

Drugs in Phase 2 Trials (5)

abiraterone (zytiga) (1 trial)

copper (cu-7) (1 trial)

eplerenone (inspra) (1 trial)

Filgrastim (neupogen) (2 trials)

slx-2101 (1 trial)

Drugs in Other Trials (9)

b multivitamins (1 trial)

calcium (1 trial)

cyanocobalamin (berocca) (3 trials)

folic acid (2 trials)

phytosterol (1 trial)

pyridoxine (2 trials)

resistant starch (1 trial)

vancomycin (Vancocin) (1 trial)

vitamin d3 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 3)

Alzheimer Disease (Phase 3)

Anemia (Phase 4)

Anemia, Iron-Deficiency (Phase 4)

Arteriosclerosis (Phase 4)

Atrial Fibrillation (Phase 2)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Transitional Cell (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Coronary Restenosis (Phase 3)

Dementia (Phase 3)

Erectile Dysfunction (Phase 3)

Essential Hypertension (Phase 3)

Heart Diseases (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Hyperkinesis (Phase 3)

Hypertension (Phase 3)

Infections (Phase 4)

Inflammation (Phase 4)

Influenza, Human (Phase 4)

Kidney Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Melanoma (Phase 3)

Myocardial Ischemia (Phase 4)

Neuritis (Phase 2)

Optic Neuritis (Phase 2)

Pancreatic Neoplasms (Phase 3)

Photosensitivity Disorders (Phase 1)

Prostatic Neoplasms (Phase 2)

Raynaud Disease (Phase 2)

Recurrence (Phase 2)

Telangiectasia, Hereditary Hemorrhagic (Phase 3)

Telangiectasis (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Uveal Neoplasms (Phase 3)

Wilms Tumor (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 41
  • # of Trial APIs: 44